BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27687793)

  • 1. Bcl-xL inhibition - a novel strategy for glioma therapy.
    Karpel-Massler G; Siegelin MD
    Aging (Albany NY); 2016 Sep; 8(9):1830-1831. PubMed ID: 27687793
    [No Abstract]   [Full Text] [Related]  

  • 2. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
    Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
    Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
    Karpel-Massler G; Ramani D; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2016 Jun; 7(23):33512-28. PubMed ID: 27172899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
    Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma.
    Nguyen TT; Torrini C; Shang E; Shu C; Mun JY; Gao Q; Humala N; Akman HO; Zhang G; Westhoff MA; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38483541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.
    Karpel-Massler G; Banu MA; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2016 Mar; 7(11):12791-805. PubMed ID: 26872380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
    Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withania somnifera Suppresses Tumor Growth of Intracranial Allograft of Glioma Cells.
    Kataria H; Kumar S; Chaudhary H; Kaur G
    Mol Neurobiol; 2016 Aug; 53(6):4143-4158. PubMed ID: 26208698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
    Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
    Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
    Shoemaker AR; Oleksijew A; Bauch J; Belli BA; Borre T; Bruncko M; Deckwirth T; Frost DJ; Jarvis K; Joseph MK; Marsh K; McClellan W; Nellans H; Ng S; Nimmer P; O'Connor JM; Oltersdorf T; Qing W; Shen W; Stavropoulos J; Tahir SK; Wang B; Warner R; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    Cancer Res; 2006 Sep; 66(17):8731-9. PubMed ID: 16951189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells.
    Ye L; Yuan G; Xu F; Sun Y; Chen Z; Chen M; Li T; Sun P; Li S; Sun J
    Tumour Biol; 2015 May; 36(5):3447-55. PubMed ID: 25542230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective BCL-X
    Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
    Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
    Jin J; Xiong Y; Cen B
    Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells.
    Cuevas P; Díaz-González D; Sánchez I; Lozano RM; Giménez-Gallego G; Dujovny M
    Neurol Res; 2006 Mar; 28(2):127-30. PubMed ID: 16551428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.